Objective:To explore therapeutic effects of trimetazidine combined atorvastatin calcium on chronic heart failure (CHF) .Methods:According to random number table ,a total of 80 CHF patients were randomly and equally divided into routine treatment group and combined treatment group (received trimetazidine and atorvastatin calcium based on routine treatment group) .NYHA class improvement ,6min walking distance (6MWD) ,left ventricular ejection fraction (LVEF) , left ventricular end‐systolic dimension (LVESd ) , plasma levels of brain natriuretic peptide (BNP ) , C reactive protein (CRP) and adverse drug reactions (ADR) were compared between two groups before and six months after treatment .Re‐sults:Compared with routine treatment group after treatment ,there was significant rise in total effective rate of heart function improvement (77.5% vs .95.0% ) in combined treatment group , P=0.023. Compared with routine treatment group ,there were significant rise in 6MWD [ (346.6 ± 47.3) m vs .(396.4 ± 49.2) m] and LVEF [ (44.5 ± 4.8)% vs . (49.3 ± 5.4)% ] ,and significant reductions in LVESd [ (54.2 ± 4.1) mm vs .(51.1 ± 4.3) mm] ,plasma levels of BNP [ (348.4 ± 61.3) pg/ml vs .(251.4 ± 53.6) pg/ml] and CRP [ (9.1 ± 2.2) mg/L vs .(6.4 ± 1.6) mg/L] in combined treatment group , P<0.05 or <0.01. No severe ADR was found in two groups .Conclusion:Trimetazidine combined ator‐vastatin calcium can significantly improve cardiac function and exercise capacity ,improve quality of life and ventricular re‐modeling in CHF patients ,it's safe and reliable ,which is worth extending .